<DOC>
	<DOCNO>NCT00081874</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose RAD001 give treatment leukemia , mantle cell lymphoma , myelofibrosis . Another goal learn effective dose find treatment .</brief_summary>
	<brief_title>RAD001 Relapsed Refractory AML , ALL , CML Blastic-Phase , Agnogenic Myeloid Metaplasia , CLL , T-Cell Leukemia , Mantle Cell Lymphoma</brief_title>
	<detailed_description>RAD001 new drug design block protein important development growth cancer . If eligible take part study , receive treatment RAD001 mouth every day long stay study . Four week ( 28 day ) treatment consider one course therapy . The first 3 6 participant study receive low dose RAD001 . If dose safe , next group 3 6 patient receive double dose first 3-6 participant . If dose safe , participant start treatment dose . While study , weekly blood test ( 2 teaspoon ) . Bone marrow aspirate and/or biopsy , x-rays and/or scan perform every 4-12 week often physician feel necessary . A physical exam do Weeks 5 , 7 , 9 , 11 anytime physician see fit . Vital sign take every week . You may remove study n't respond 4 course therapy , intolerable side effect occur , disease worsens . Your dose may temporarily hold decreased certain side effect occur . If benefitting therapy , may continue indefinitely long continue benefit . Once come study , physical exam , measurement vital sign , blood test ( 2 teaspoon ) , bone marrow aspirate and/or biopsy , x-rays , and/or scan do . This investigational study . The FDA authorize RAD001 use research . A total 70 -125 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients advance , relapse refractory : acute leukemia ( AML , ALL ) , MDS , CMML transformation great equal 10 % peripheral blood/bone marrow blast , CML blastic phase , agnogenic myeloid metaplasia ( AMM ) , CLL , Tcell leukemia , mantle cell lymphoma . 2 . Serum bilirubin &lt; = 2 mg/dL , SGOT SGPT &lt; 3 upper limit normal , serum creatinine &lt; = 2 mg/dL , unless consider due organ leukemic involvement Gilbert 's syndrome 3 . The effect RAD001 develop human fetus unknown . For reason inhibitor mRNA translation know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 4 . Ability understand willingness sign write informed consent document . 1 . Patients cytotoxic chemotherapy ( hydroxyurea corticosteroid ) radiotherapy within 7 day prior enter study . 2 . Patients may receive cytotoxic investigational agent . 3 . History allergic reaction attribute compound similar chemical biologic composition RAD001 . RAD001 must administer patient know hypersensitivity everolimus , sirolimus excipients . Excipients include butylate hydroxytoluene , magnesium stearate , hydroxypropylmethylcellulose , crospovidone , lactose . 4 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 5 . Pregnant woman exclude study RAD001 potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother RAD001 , breastfeed discontinue mother treated RAD001 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Relapsed Refractory Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphocytic Leukemia</keyword>
	<keyword>Chronic Myeloid Leukemia Blastic-Phase</keyword>
	<keyword>Agnogenic Myeloid Metaplasia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>T-Cell Leukemia</keyword>
	<keyword>RAD001</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
</DOC>